Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.54 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114736 | 1.00 | FOLH1 (0.54) | FOLH1SLC15A2GNPATSLC6A5NOD1 | |
| SCHEMBL27860271 | 1.00 | FOLH1 (0.54) | FOLH1SLC15A2GNPATSLC6A5NOD1 | |
| SCHEMBL1455499 | 0.94 | FOLH1 (0.62) | FOLH1SLC15A2GNPATSLC6A5NOD1 | |
| SCHEMBL3460653 | 0.94 | FOLH1 (0.62) | FOLH1SLC15A2GNPATSLC6A5NOD1 | |
| SCHEMBL1455498 | 0.94 | FOLH1 (0.62) | FOLH1SLC15A2GNPATSLC6A5NOD1 | |
| SCHEMBL27814763 | 0.93 | SLC15A2 (0.56) | FOLH1SLC15A2GNPATSLC6A5NOD1 | |
| SCHEMBL27814755 | 0.93 | SLC15A2 (0.56) | FOLH1SLC15A2GNPATSLC6A5NOD1 | |
| Ammonia Solution, Strong SCHEMBL4293159 | 0.92 | FOLH1 (0.60) | FOLH1SLC15A2GNPATSLC6A5NOD1 | |
| Ammonia Solution, Strong SCHEMBL4293156 | 0.92 | FOLH1 (0.60) | FOLH1SLC15A2GNPATSLC6A5NOD1 | |
| SCHEMBL30964327 | 0.88 | SLC15A2 (0.62) | FOLH1SLC15A2GNPATSLC6A5CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2010-03-04 | — | — | US | claimed |
| EP-1898943-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | Hadasit Medical Research Services & Development Ltd. (IL) | 2008-03-19 | — | — | EP | claimed |
| WO-2006126188-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2006-11-30 | — | — | WO | claimed |
| US-20040116655-A1 | Novel polypeptides and anti-hiv drugs containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2004-06-17 | — | — | US | claimed |
| EP-1323730-A1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2003-07-02 | — | — | EP | claimed |
| EP-0677061-B1 | POLYPEPTIDES AND ANTI-HIV AGENTS PREPARED THEREFROM | SEIKAGAKU KOGYO CO LTD (JP) | 1999-03-03 | — | — | EP | claimed |
| US-5776899-A | Polypeptide and anti-HIV agent prepared therefrom | SEIKAGAKU CORPORATION (JP) | 1998-07-07 | — | — | US | claimed |
| CN-1038841-C | Polypeptide and anti-hiv agent prepared therefrom | SEIKAGAKU CO (JP) | 1998-06-24 | — | — | CN | claimed |
| CN-1116427-A | Novel polypeptide and anti-HIV agent prepared from the same | SEIKAGAKU KOGYO CO LTD (JP) | 1996-02-07 | — | — | CN | claimed |
| EP-0677061-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-10-18 | — | — | EP | claimed |
| WO-1995010534-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-04-20 | — | — | WO | claimed |
| EP-3011961-B1 | 4F-BENZOYL-TN14003 FOR THE MOBILISATION OF HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF TRANSPLANTATION | BIOKINE THERAPEUTICS LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-2841084-B1 | CXCR4 ANTAGONIST PEPTIDE FOR USE IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2018-05-30 | — | — | EP | disclosed |
| US-9439942-B2 | Peptides and use thereof in the treatment of large cell lung cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2016-09-13 | — | — | US | disclosed |
| US-9427456-B2 | Peptide therapy for increasing platelet levels | BIOKINE THERAPEUTICS LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| CN-1116427-A | Novel polypeptide and anti-HIV agent prepared from the same | SEIKAGAKU KOGYO CO LTD (JP) | 1996-02-07 | — | — | CN | disclosed |
| EP-0677061-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-10-18 | — | — | EP | disclosed |
| EP-0677061-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995010534-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-04-20 | — | — | WO | disclosed |
| WO-1995010534-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | CXCR4, CXCL12, CXCR5 | FOLH1 3082/4885SLC15A2 317/4885GNPAT 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.